What do liquid biopsies offer us for breast cancer patients?
|
|
- Juliet Phillips
- 5 years ago
- Views:
Transcription
1 What do liquid biopsies offer us for breast cancer patients? Isaac Garcia-Murillas Breast Cancer Now Research Centre, The institute of Cancer Research, London, UK
2 Molecular Analysis of breast cancer Invasive Expensive Processing takes time Non-invasive assessment Less expensive Rapid purification Whole picture Surrogate when anatomic biopsies are not feasible
3 Liquid Biopsies Siravegnaet al Nat Rev Clin Oncol, 2017
4 Circulating Nucleic acids in cancer: cfdna and ctdna Crowley et al Nat Rev Clin Oncol, 2013
5 Analysing genomic aberrations in ctdna from breast cancer patients De Mattos-Arruda, Mol Oncol 2015
6 Clinical applications of ctdna analysis in breast cancer Two very different settings of therapy Early breast cancer Adjuvant therapy to treat micro-metastatic disease Advanced breast cancer Metastatic therapy to treat overt metastatic disease More genetically homogeneous More genetically diverse
7 Clinical applications of ctdna analysis in breast cancer Wan et al Nat Rev Cancer, 2017
8 Clinical applications of ctdna analysis in breast cancer Prediction of relapse in early breast cancer Patient Stratification based on alterations Tumour heterogeneity Identification of Mechanisms of resistance to therapy Liquid biopsies in immunotherapy trials
9 Prediction of relapse in early breast cancer Olsson et al EMBO Med, 2015
10 Prediction of relapse in early breast cancer
11 Prediction of relapse in early breast cancer ChemoNEAR study design Garcia-Murillas et al STM, 2015
12 Prediction of relapse in early breast cancer Predicting early relapsebaseline plasma (DFS) Predicting early relapsesingle post-surgery (DFS) Predicting early relapsemutation tracking (DFS) 78% (43/55) ctdna detection in baseline plasma DNA Detection associated with ER negative and high grade Mutation detection in the immediate post-surgical sample identifies early relapse but misses later relapses Dynamic mutation tracking is highly accurate in predicting relapse
13 Prediction of relapse in early Predicting early relapsesingle post-surgery (OS) breast cancer Predicting early relapsemutation tracking (OS) All patients with ctdna detected in a single postsurgical time point relapsed and died (7/7, 100% specificity), with modest 39% (7/18) sensitivity for relapse. All patients with ctdna detected at any time point in serial sampling relapsed in the followup period (14/14, 100% specificity), with 78% (14/18) sensitivity for relapse. Detection of ctdna in the adjuvant setting has a high predictive value for future relapse and death from breast cancer.
14 Clinical applications of ctdna analysis in breast cancer Prediction of relapse in early breast cancer Patient Stratification based on alterations Tumour heterogeneity Identification of Mechanisms of resistance to therapy Liquid biopsies in immunotherapy trials
15 Patient Stratification based on alterations plasmamatch
16 Patient Stratification based on alterations ABC-BIO Frequency of mutations and amplifications detected in ctdna from plasma samples in ABC-BIO % PIK3CA ESR1 AKT1 HER2 mut HER2 amp Mutations and Amplification Fribbens et al, unpublished
17 Patient Stratification based on alterations plasmamatch
18 Clinical applications of ctdna analysis in breast cancer Prediction of relapse in early breast cancer Patient Stratification based on alterations Tumour heterogeneity Identification of Mechanisms of resistance to therapy Liquid biopsies in immunotherapy trials
19 Tumour heterogeneity De Mattos-Arruda Mol Oncol, 2015
20 Tumour heterogeneity Genetic heterogeneity as the engine of targeted therapy resistance Mutation frequency Wand et al Nature, 2014 Turner et al Lancet Oncol, 2012
21 Clinical applications of ctdna analysis in breast cancer Prediction of relapse in early breast cancer Patient Stratification based on alterations Tumour heterogeneity Identification of Mechanisms of resistance to therapy Liquid biopsies in immunotherapy trials
22 Identification of Mechanisms of resistance to therapy ESR1mutations as important resistance mechanism in patients treated with endocrine therapy Cluster of mutations in amino acids in ligandbinding domain(lbd) reported in AI pretreated patients Mutations in ligand binding domain activate ER ligand independent signalling Resistance to aromatase inhibitors Potentially sensitive to ER degraders ESR1 mutations occur in ~20% of endocrine resistant ER positive breast cancer Toy et al Nature Genetics, 2013 Robinson et al Nature Genetics,2013
23 Identification of Mechanisms of resistance to therapy ESR1mutations in ctdna and resistance to subsequent aromatase inhibitor (AI) ESR1 mutations rarely acquired during adjuvant AI but are commonly selected by therapy for metastatic disease Evidence that mechanisms of resistance to targeted therapy may be different between the treatment of micro-metastatic and overt metastatic cancer. Schiavon et al STM, 2015
24 Identification of Mechanisms of resistance to therapy SoFEA/PALOMA-3 Does detection of ESR1 mutations in plasma predict for relative sensitivity to fulvestrant vs exemestane? Is CDK4/6 inhibition effective in ESR1 mutant cancers?
25 Identification of Mechanisms of resistance to therapy SoFEA 39.1% patients (63/161) had ESR1 mutations detected in plasma Detection of ESR1mutations in plasma DNA suggests relative resistance to exemestane, and relative sensitivity to fulvestrant Patients with no ESR1 mutation may derive further benefit from exemestane as well as fulvestrant Fribbens et al JCO, 2015
26 Identification of Mechanisms of resistance to therapy PALOMA % patients (91/360) had ESR1 mutations detected in plasma Palbociclib and fulvestrant appears equally effective in patients with or without ESR1 mutations Fribbens et al JCO, 2015
27 Clinical applications of ctdna analysis in breast cancer Prediction of relapse in early breast cancer Patient Stratification based on alterations Tumour heterogeneity Identification of Mechanisms of resistance to therapy Liquid biopsies in immunotherapy trials
28 Liquid Biopsies on immunotherapy trials C-TRAK TNBC
29 Final Remarks
30 The patients that participate on the studies The Royal Marsden Hospital/The Institute of Cancer Research Molecular Oncology Lab:Nick Turner, Alex Pearson, Sarah Hrebien, Matthew Beaney, Claire Swift, Monee Shamsher, Ben O Leary, Iñaki Comino-Mendez, Gaia Schiavon, Charlotte Fribbens, Neha Chopra, Ros Cutts Generations Lab: Katarzyna Tomczyk Histopathology Lab: Frances Daley Acknowledgements
Disclosure. Summary. Circulating DNA and NGS technology 3/27/2017. Disclosure of Relevant Financial Relationships. JS Reis-Filho, MD, PhD, FRCPath
Circulating DNA and NGS technology JS Reis-Filho, MD, PhD, FRCPath Director of Experimental Pathology, Department of Pathology Affiliate Member, Human Oncology and Pathogenesis Program Disclosure of Relevant
More informationCirculating tumour DNA in breast cancer. Kathleen Burke, PhD Bioinformatics Postdoctoral Fellow Laboratory of Dr. Jorge Reis-Filho
Circulating tumour DNA in breast cancer Kathleen Burke, PhD Bioinformatics Postdoctoral Fellow Laboratory of Dr. Jorge Reis-Filho Conflicts of Interest I have no financial relationships to disclose I will
More informationPredicting outcome in metastatic breast cancer
Predicting outcome in metastatic breast cancer Aleix Prat, MD, PhD Medical Oncology Department Translational Genomics and Targeted Therapeutics in Solid Tumors Monday, 15 th January, Manchester, UK Disclosures
More informationPros and cons of liquid biopsy: Ready to replace tissue?
Pros and cons of liquid biopsy: Ready to replace tissue? 2-Day Molecular Biologists Symposium: Liquid biopsies Federico Rojo Enterprise Interest No disclosures. Biological limitations for molecular testing:
More informationApproximately 70% of breast
Josh Lauring and Antonio C. Wolff Evolving Role of the Estrogen Receptor as a Predictive Biomarker: ESR1 Mutational Status and Endocrine Resistance in Breast Cancer (J Clin Oncol 2016;34(25):2950 2952.)
More informationWhen is Chemotherapy indicated in Advanced Luminal Breast Cancer?
When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore
More informationTreatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
More informationRound Table: Tissue Biopsy versus Liquid Biopsy. César A. Rodríguez Hospital Universitario de Salamanca-IBSAL
Round Table: Tissue Biopsy versus Liquid Biopsy César A. Rodríguez Hospital Universitario de Salamanca-IBSAL Introduction Classic Advantages of liquid biopsy collection over standard biopsy Standard biopsy
More informationplasma MATCH Andrew Wardley,
in partnership with plasma MATCH A multiple parallel cohort, open-label, multi-centre phase IIa clinical trial of circulating tumour DNA screening to direct targeted therapies in patients with advanced
More informationLiquid Biopsy. Jesus Garcia-Foncillas MD PhD. Director
Liquid Biopsy Jesus Garcia-Foncillas MD PhD Director Main issues about liquid biopsies New paradigm: Precision Medicine Heterogeneity & Dynamics Surrogate mirror for the tumor CTCs in colon cancer ctdna:
More informationMechanisms of hormone drug resistance
Mechanisms of hormone drug resistance Ljiljana Stamatović Institute for Oncology and Radiology of Serbia Tenth UMOS Conference, Belgrade, 16-17 th May 2015. Hormone receptor-positive breast cancer (HR+
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationCirculating Tumor DNA in GIST and its Implications on Treatment
Circulating Tumor DNA in GIST and its Implications on Treatment October 2 nd 2017 Dr. Ciara Kelly Assistant Attending Physician Sarcoma Medical Oncology Service Objectives Background Liquid biopsy & ctdna
More informationConsensus statement between CM-Path, CRUK and the PHG Foundation following on from the Liquid Biopsy workshop on the 8th March 2018
Consensus statement between CM-Path, CRUK and the PHG Foundation following on from the Liquid Biopsy workshop on the 8th March 2018 Summary: This document follows on from the findings of the CM-Path The
More informationEndocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it?
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education
More informationJohns Hopkins Clinical Update Webinar
Johns Hopkins Clinical Update Webinar Ben Ho Park, M.D., Ph.D. Department of Oncology Johns Hopkins University February 2015 This presentation is the intellectual property of the author/presenter. Contact
More informationTRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer
TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive
More informationSYSTEMIC THERAPY OPTIONS FOR BREAST CANCER IN 2014
SYSTEMIC THERAPY OPTIONS FOR BREAST Oncology Day 2014 CANCER IN 2014 Dr. Katherine Enright, M.D., M.P.H., F.R.C.P.(C) Katherine.enright@Trilliumhealthpartners.ca OBJECTIVES 1. Outline an approach to the
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationMultimedia Appendix 6 Educational Materials Table of Contents. Intervention Educational Materials Audio Script (version 1)
Multimedia Appendix 6 Educational Materials Table of Contents Intervention Educational Materials... 1 Audio Script (version 1)... 1 Text (version 1)... 5 Slides (version 1)... 17 Audio Script (version
More informationThe feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients
The feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients ASSC Scientific Meeting 13 th October 2016 Prof Andrew Barbour UQ SOM
More informationEndocrine treatment might NOT be the preferred option in Hrpos MBC. Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015
Endocrine treatment might NOT be the preferred option in Hrpos MBC Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015 Overall survival not improved by the AI treatment Benefit in
More informationGenomic tests to personalize therapy of metastatic breast cancers. Fabrice ANDRE Gustave Roussy Villejuif, France
Genomic tests to personalize therapy of metastatic breast cancers Fabrice ANDRE Gustave Roussy Villejuif, France Future application of genomics: Understand the biology at the individual scale Patients
More informationManejo do câncer de mama RH+ na adjuvância: o que há de novo?
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico Manejo do câncer de mama RH+ na adjuvância: o que há de novo? INGRID A. MAYER, MD, MSCI Assistant Professor of Medicine Director,
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationInibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici
Inibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici Laura Orlando UOC Oncologia & Breast Unit Brindisi Verona 22/04/2016 Summary Studi con
More informationAggiornamenti tra ricerca e clinica: il carcinoma della mammella
Aggiornamenti tra ricerca e clinica: il carcinoma della mammella Filippo Montemurro Unit of (INCO) Fondazione del Piemonte per l Oncologia Candiolo Cancer Institute (IRCCs) Research Needs in Breast Cancer
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationEndocrine Therapy for Advanced Breast Cancer (ABC) Dr Yoon-Sim YAP Division of Medical Oncology, National Cancer Centre Singapore
Endocrine Therapy for Advanced Breast Cancer (ABC) Dr Yoon-Sim YAP Division of Medical Oncology, National Cancer Centre Singapore Outline Guidelines and Evolving Clinical Treatment Landscape for HR+ HER2-
More informationIntroduction to liquid biopsies. Rachel Butler All Wales Genetics Laboratory
Introduction to liquid biopsies Rachel Butler All Wales Genetics Laboratory What is cell free DNA? Non-Invasive Prenatal Testing (NIPT) Extract DNA Genetic alterations detectable in circulating cell-free
More informationTargeting CDK 4/6. Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine
2016.04.30 GBCC Education Symposium Targeting CDK 4/6 Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine Contents Cyclins -CDKs in cell cycle control CDK 4/6 in breast cancer Preclinical
More informationLa biopsia liquida. Aldo Scarpa. Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro
La biopsia liquida Aldo Scarpa Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro Azienda Ospedaliera Universitaria Integrata di Verona Obstacles to precision oncology Genomic heterogeneity
More informationLa via del segnale PI3K/AKT/mTOR Inibitori di mtor nel carcinoma mammario
La via del segnale PI3K/AKT/mTOR Inibitori di mtor nel carcinoma mammario Alessandra Modena U.O.C. Oncologia Medica Direttore: Dott.ssa Stefania Gori Ospedale Sacro Cuore - Don Calabria 29 novembre 2016
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationMetastatic breast cancer: sequence of therapies
Metastatic breast cancer: sequence of therapies Clinical Case Discussion Nadia Harbeck, MD PhD Breast Center, Department of Gynecology and Obstetrics University of Munich, Ludwig-Maximilians University
More informationCell-free tumor DNA for cancer monitoring
Learning objectives Cell-free tumor DNA for cancer monitoring Christina Lockwood, PhD, DABCC, DABMGG Department of Laboratory Medicine 1. Define circulating, cell-free tumor DNA (ctdna) 2. Understand the
More informationASCO 2017 WEBCAST. Elacestrant (RAD1901) June, 4, 2017
ASCO 2017 WEBCAST Elacestrant (RAD1901) June, 4, 2017 NASDAQ: RDUS Disclaimer: RAD1901 is an investigational agent Please refer to the ASCO 2017 poster for complete details Safe Harbor Any statements made
More informationClinical Oncology - Science in focus - Editorial. Understanding oestrogen receptor function in breast cancer, and its interaction with the
Clinical Oncology - Science in focus - Editorial TITLE: Understanding oestrogen receptor function in breast cancer, and its interaction with the progesterone receptor. New preclinical findings and their
More informationAn Oncology Strategy for IMI. Stefan J Scherer M.D.;Ph.D IMI Stakeholder Meeting Brussels, Belgium
An Oncology Strategy for IMI Stefan J Scherer M.D.;Ph.D 28.09.2016 IMI Stakeholder Meeting Brussels, Belgium Strategic Themes of the Oncology SGG The mission and vison of the SGG Oncology is to define
More informationDr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester
Dr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester dsg6@le.ac.uk CFDNA/CTDNA Circulating-free AS A LIQUID DNA BIOPSY (cfdna) Tumour Biopsy Liquid Biopsy
More informationThe Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer
The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer Laura Spring, MD Breast Medical Oncology Massachusetts General Hospital Primary Mentor: Dr. Aditya Bardia
More informationPrevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients
Takeshita et al. BMC Cancer (2017) 17:786 DOI 10.1186/s12885-017-3779-2 RESEARCH ARTICLE Open Access Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients Takashi
More informationCDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018
CDx in oncology Prof. Christophe Le Tourneau, MD, PhD Institut Curie Paris & Saint-Cloud France Head, Department of Drug Development and Innovation (D 3 i) INSERM U900 Research unit Versailles Saint-Quentin-en-Yvelines
More informationClinical Spotlight Key Advances in Hormone Receptor Positive Breast Cancer: Updates From the 2018 Oncology Annual Meeting in Chicago
Clinical Spotlight Key Advances in Hormone Receptor Positive Breast Cancer: Updates From the 2018 Oncology Annual Meeting in Chicago Reference Slide Deck Abstract 1000 Abstract 1001 Abstract 1002 Abstract
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar The opportunity of the neoadjuvant approach L. Gianni, Milan, I XII Michelangelo Foundation Seminar Milano, October 12, 2012 The opportunity of the neoadjuvant approach
More informationOutline of the presentation
Outline of the presentation Breast cancer subtypes and classification Clinical need in estrogen-positive (ER+) metastatic breast cancer (mbc) Sulforaphane and SFX-01: the preclinical evidence STEM Phase
More informationBreast cancer pathology
Breast cancer pathology Giancarlo Pruneri, M.D. National Cancer Institute (INT) Milan University of Milan, School of Medicine Giancarlo.Pruneri@unimi.it Currently accepted prognostic/predictive parameters
More informationCirculating Tumor DNA and Circulating Tumor Cells for Management (Liquid Biopsy) of Solid Tumor Cancers
NOTE: This policy is not effective until December 1, 2018. To view the current policy, click here. Medical Policy Manual Laboratory, Policy No. 46 Circulating Tumor DNA and Circulating Tumor Cells for
More informationCurrent Optimal Sequence and Duration of Endocrine Treatment
[Symposium 7] Present and Future of Endocrine Therapy 07 Apr, 2018@GBCC Current Optimal Sequence and Duration of Endocrine Treatment Breast Oncology Center The Cancer Institute Hospital of JFCR Shinji
More informatione-session 381 BCY3 - Highlights of the 3rd ESO-ESMO Breast Cancer in Young Women International Conference
Expert: Dr Olivia Pagani, Oncology Institute of Southern Switzerland, Lugano, Switzerland Discussant: Dr Fedro Alessandro Peccatori, European Institute of Oncology, Milan, Italy e-session 381 BCY3 - Highlights
More informationTumor Gene Sequencing: Ready for a Revolution?
Tumor Gene Sequencing: Ready for a Revolution? Philippe Aftimos, M.D. Clinical Pharmacology Unit Institut Jules Bordet Brussels, Belgium ICBD Antwerp February 7 th, 2015 IHC: Historical Biomarkers Cold
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationOnline-Only Supplementary Materials
Online-Only Supplementary Materials Online-Only Supplementary Methods: Eligibility Criteria and Study Endpoints and Assessments Supplementary Table 1. Demographic and Baseline Characteristics in Patients
More informationYoungnam Cho. National Cancer Center Biomarker Branch
Youngnam Cho National Cancer Center Biomarker Branch Contents 1. Liquid Biopsy 2. Circulating Tumor Cells from Blood 3. Cell-free DNA from Blood 1. Liquid biopsy Cancer Diagnosis IMAGING TISSUE BIOPSY
More informationASCO 2017 BREAST CANCER HIGHLIGHTS
Post-ASCO 24 th June 2017, Dolce La Hulpe, Belgium ASCO 2017 BREAST CANCER HIGHLIGHTS Martine J. Piccart-Gebhart, MD, PhD Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast
More informationQué hemos aprendido hasta hoy? What have we learned so far?
Qué hemos aprendido hasta hoy? What have we learned so far? Luís Costa Hospital de Santa Maria & Instituto de Medicina Molecular Faculdade de Medicina de Lisboa Disclosures Research Grants: Amgen; Novartis;
More informationNCRI Biomarkers & Imaging CSG Cell-free DNA workshop
NCRI Biomarkers & Imaging CSG Cell-free DNA workshop Workshop Report Christie Education Centre, Manchester 30th January 2014 Sponsored by Workshop summary 86 delegates from a variety of specialities attended
More informationIntegrated platform for liquid biopsy-based personalized cancer medicine
Integrated platform for liquid biopsy-based personalized cancer medicine Dr. Bernhard Polzer Fraunhofer ITEM-Regensburg Personalized Tumor Therapy Personalized cancer therapy Primary tumor single tumor
More informationManagement of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers
Review Article Page 1 of 10 Management of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers Roger K. C. Ngan Department of Clinical Oncology, Queen Elizabeth
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationUse of Ovarian Suppression and Ablation in Breast Cancer Treatment
Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Dr Marina Parton Consultant Medical Oncologist Royal Marsden and Kingston Hospitals Overview Breast cancer phenotypes Use of ovarian manipulation
More informationHormonal Management of Metastatic Breast Cancer
Hormonal Management of Metastatic Breast Cancer Dr. Khaled Abulkhair, PhD Medical Oncology SCE, Royal College, UK Ass. Professor of Clinical Oncology Mansoura University, Egypt Case For Discussion A 63
More informationHeterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
Received Dec Accepted Apr Published May DOI:.8/ncomms79 OPEN Heterogeneity and clinical significance of ESR mutations in ER-positive metastatic breast cancer patients receiving fulvestrant Jill M. Spoerke,
More informationUpdate mbc. endokrine Therapie
Update mbc endokrine Therapie HR neg ER pos Endokrine Resistenz Endokrine Therapie 1 st line Postmenopause AI/Tam/Fulvestrant 84% AI+ Fulvestrant 33% AI (Tam) + Everolimus 84% AI + CDK4/6 92% Prämenopause
More informationTranslational Platform for the Development of Targeted Therapeutics
Translational Platform for the Development of Targeted Therapeutics Ondřej Kalous, MD Associate Project Scientist UCLA Translational Oncology Research Laboratories (TORL) Jonsson Comprehensive Cancer Center
More informationBreast Cancer: ASCO Poster Review
Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy
More informationFulvestrant: cuándo y dónde usarlo? Dra. S. López-Tarruella
Fulvestrant: cuándo y dónde usarlo? Dra. S. López-Tarruella FULVESTRANT mechanism of action Carlson et al Clin Breast Cancer 2005; Howell Crit Rev Oncol Hematol 2016; Robertson et al Cancer Res 2001; De
More informationBreast cancer treatment
Report from the San Antonio Breast Cancer Symposium Breast cancer treatment Determining the best options for select patient groups Sara Soldera, MD, Resident; Nathaniel Bouganim, MD, FRCPC, Medical Oncologist;
More informationHormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension?
Hormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension? Ivana Sestak, PhD Centre for Cancer Prevention Wolfson Institute of Preventive Medicine Queen Mary University London
More informationPro: Hormone Therapy in HR positive MBC is the preferred option!
Pro: Hormone Therapy in HR positive MBC is the preferred option! Alexandru Eniu, MD, PhD Medical Oncologist Head, Day Hospital Unit Department of Breast Tumors Cancer Institute Ion Chiricuţă Cluj-Napoca,
More informationEndocrine Therapy of Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Version 2002: Gerber / Friedrichs
More informationASCO 2018 Breast Cancer Highlights
ASCO 2018 Breast Cancer Highlights Angie DeMichele, MD, MSCE Jill & Alan Miller Endowed Chair in Breast Cancer Excellence Professor of Medicine and Epidemiology Co-Leader, Breast Cancer Program, Abramson
More informationMetastatic HR+ Breast Cancer - CDK 4/6 Inhibitors Charting the Path. Sandy Sehdev MD FRCPC
Metastatic HR+ Breast Cancer - CDK 4/6 Inhibitors Charting the Path Sandy Sehdev MD FRCPC Objectives To understand the approach to the treatment of hormone sensitive metastatic breast cancer and the use
More informationCharacterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser
Characterisation of structural variation in breast cancer genomes using paired-end sequencing on the Illumina Genome Analyser Phil Stephens Cancer Genome Project Why is it important to study cancer? Why
More informationColorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann
Colorectal Cancer in 2017: From Biology to the Clinics Rodrigo Dienstmann MOLECULAR CLASSIFICATION Tumor cell Immune cell Tumor microenvironment Stromal cell MOLECULAR CLASSIFICATION Biomarker Tumor cell
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationOncology. A CME-certified Supplement to the. Journal of the National Comprehensive Cancer Network. Program Overview/Statement of Need
JNCCN Volume 16 1 Journal of the National Comprehensive Cancer Network A CME-certified to the Journal of the National Comprehensive Cancer Network Program Overview/Statement of Need Recently updated guidelines
More informationBiopsia Líquida: Oncología en Tiempo Real. Federico Rojo Fundación Jiménez Díaz
Biopsia Líquida: Oncología en Tiempo Real Federico Rojo Fundación Jiménez Díaz Liquid Biopsy in Cancer Liquid Biopsy in Cancer Publication Date: April 5, 2016 Blood Tests replace Surgical Biopsies to create
More informationOpen Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right
More informationLUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia
LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%
More informationHormone therapy in Breast Cancer patients with comorbidities
Hormone therapy in Breast Cancer patients with comorbidities Diana Crivellari Centro di Riferimento Oncologico Aviano- ITALY Madrid November 9th, 2007 Main issues Comorbidities in elderly women Hormonal
More informationPROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions
PROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions Outline Prognostic and diagnostic value of pathologic and molecular alterations in prostate cancer Current status
More informationCTC molecular characterization: Are we ready to move forward with clinical testing?
CTC molecular characterization: Are we ready to move forward with clinical testing? Michail Ignatiadis MD, PhD Jules Bordet Institute, Université Libre de Bruxelles Brussels, Belgium Breast cancer: Diagnostics
More informationMedical Coverage Policy Circulating Tumor DNA and. Circulating Tumor Cells for Cancer Management (Liquid Biopsy)
Medical Coverage Policy Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy) EFFECTIVE DATE: 12 01 2016 POLICY LAST UPDATED: 07 17 2018 OVERVIEW Circulating tumor DNA
More informationLA MALATTIA METASTATICA. La malattia HR positiva/her2 negativa: quale terapia di I linea? Come scegliere? Jennifer Foglietta P.O.
LA MALATTIA METASTATICA La malattia HR positiva/her2 negativa: quale terapia di I linea? Come scegliere? Jennifer Foglietta P.O. Narni-Amelia (TR) Outline Re-testing metastatic disease Chemo- vs endocrine-therapy
More informationAdjuvant Endocrine Therapy: How Long is Long Enough?
Adjuvant Endocrine Therapy: How Long is Long Enough? Harold J. Burstein, MD, PhD Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts hburstein@partners.org I have no conflicts to
More informationTargeting the PI3 kinase mtor pathway in breast cancer. Dr Nicholas Turner. Madrid 2014
Targeting the PI3 kinase mtor pathway in breast cancer Dr Nicholas Turner Madrid 2014 Relevant disclosures Honoraria and/or Research funding Novartis AstraZeneca Roche Targeting PI3 kinase mtor pathway
More informationNext generation diagnostics Bringing high-throughput sequencing into clinical application
Next generation diagnostics Bringing high-throughput sequencing into clinical application Leonardo A. Meza-Zepeda, PhD Translational Genomics Group Institute for Cancer Research Leonardo.Meza-Zepeda@rr-research.no
More informationGatekeeper mutations and intra-tumoural heterogeneity in FGFR2-translocated
Gatekeeper mutations and intra-tumoural heterogeneity in FGFR2-translocated cholangiocarcinoma. Elizabeth C. Smyth 1, Irina S. Babina 2, Nicholas C. Turner 2,3*. 1 GI Unit, The Royal Marsden Hospital,
More informationCell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer
Personalized Medicine and Imaging Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer Giovanna Rossi 1,2, Zhaomei Mu 2, Alfred W. Rademaker 3, Laura
More informationHeterogeneidad tumoral. Federico Rojo
Heterogeneidad tumoral Federico Rojo Outline of the presentation Definition and evidences Intertumor heterogeneity Spatial and temporal intratumor heterogeneity Clinical implications of tumor heterogeneity.
More informationEnterprise Interest No
Enterprise Interest No SY-05 Pulmonary Pathology: Options for targeted therapy in lung cancer Liquid biopsy in thoracic oncology Where are we now? Paul Hofman Laboratory of Clinical and Experimental Pathology
More informationIntro to Cancer Therapeutics
An Intro to Cancer Therapeutics Christopher R. Chitambar, MD Professor of Medicine Division of Hematology & Oncology Froedtert and Medical College of Wisconsin Clinical Cancer Center cchitamb@mcw.edu Intro
More informationNSABP: FB-11. Shannon Puhalla, MD
NSABP: FB-11 Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib with Letrozole as Neoadjuvant Therapy in Post- Menopausal Women with Estrogen Receptor
More informationSystemic Management of Breast Cancer
Systemic Management of Breast Cancer Why Who When What How long Etc. Vernon Harvey Rotorua, June 2014 Systemic Management of Breast Cancer Metastatic Disease Adjuvant Therapy Aims of therapy Quality of
More informationEndocrine Therapy in Breast Cancer: State of the Art
Endocrine Therapy in Breast Cancer: State of the Art 12 AUG 2018 Mark Pegram, M.D. Susy Yuan-Huey Hung Professor of Oncology Associate Director for Clinical Research Director, Stanford Breast Oncology
More informationClinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
ORIGINAL ARTICLE 2018 Mar 16. [Epub ahead of print] Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy Mi Hwa Heo, Hee Kyung Kim,
More informationLate Stage Breast Cancer, Including SABCS Updates
Faculty Biography William J. Gradishar, MD, is the Betsy Bramsen Professor of Breast Oncology in the Division of Hematology and Medical Oncology, Department of Medicine at the Feinberg School of Medicine
More informationIntergenic Fusions in Advanced HR+ Breast Cancer
Intergenic Fusions in Advanced HR+ Breast Cancer Leif W. Ellisen, MD, PhD Program Director, Breast Medical Oncology Disclosures: Lief W. Ellisen, MD, PhD, has disclosed no relevant financial relationships.
More information